GIP-(3–42) does not antagonize insulinotropic effects of GIP at physiological concentrations (Q58448506)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16608883%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16608883%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16608883%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Mette M. Rosenkilde

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16608883%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jens Juul Holst

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16608883%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Astrid Plamboeck

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16608883%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jocelyn de Heer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16608883%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

11 April 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16608883%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Physiology - Endocrinology and Metabolism

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16608883%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

291

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16608883%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

E468-75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16608883%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16608883%20AND%20SRC:MED&resulttype=core&format=json

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

[Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Diminished Immunoreactive Gastric Inhibitory Polypeptide Response to a Meal in Newly Diagnosed Type I (Insulin-Dependent) Diabetics*

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Valine pyrrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced beta-cell mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00577.2005

10.1152/AJPENDO.00577.2005

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16608883%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference